Uterine Serous Carcinoma clinical trials at UCSF
1 research study open to eligible people
Showing trials for
ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma
open to eligible females ages 18 years and up
This is a Phase 2 study to evaluate the clinical activity and safety of ZN-c3 (azenosertib) in adult women with recurrent or persistent uterine serous carcinoma (USC).
San Francisco, California and other locations
Last updated: